2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
2
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Specimen Handling
267
Magnetic Resonance Spectroscopy
218
pembrolizumab
203
Carboplatin
170
Cisplatin
137
Biopsy
136
Cyclophosphamide
131
Paclitaxel
120
Nivolumab
110
Bevacizumab
104
Gemcitabine
102
Radiotherapy
85
Dexamethasone
77
Pemetrexed
75
atezolizumab
73
Fluorouracil
71
fludarabine
69
Doxorubicin
68
Leucovorin
66
Docetaxel
66
Radiation
65
Oxaliplatin
62
Rituximab
60
venetoclax
58
Prednisone
58
Cetuximab
54
durvalumab
53
Vincristine
52
Etoposide
51
130-nm albumin-bound paclitaxel
51
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
cobimetinib
×
30 days
×
Clear all
NCT03178552
2026-06-05
B-FAST
Hoffmann-La Roche
Phase 2/3
Active not recruiting
1,000 enrolled
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT04302025
2026-05-22
NAUTIKA1
Genentech, Inc.
Phase 2
Recruiting
99 enrolled